Fischel, Jean-Louis <br/><br/>
Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.  [electronic resource] 

 -  Anti-cancer drugs  Aug 2006 
 - 807-13 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0959-4973 
<br/><br/><label>Standard No.: </label>10.1097/01.cad.0000224444.23953.90  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>Cell Line, Tumor<br/>Cell Size<br/>Cell Survival--drug effects<br/>Docetaxel<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Erlotinib Hydrochloride<br/>Floxuridine--therapeutic use<br/>Humans<br/>Male<br/>Prostatic Neoplasms--drug therapy<br/>Quinazolines--therapeutic use<br/>Taxoids--therapeutic use<br/>Thymidine Phosphorylase--metabolism<br/>Thymidylate Synthase--metabolism